Objective To investigate the role of corneal exposure ratio in eyelid aesthetic assessment through the measurement by Photoshop pixel method in beauties and patients with double eyelid blepharoplasty.Methods 30 cases of female beauties and 43 cases with double eyelid blepharoplasty(23 cases with suture method and 20 cases with incision method) underwent measurement of corneal exposure ratio by Photoshop pixel method before operation and half a year after operation.The results were analyzed by SPSS 16.0 and compared between different sides or between pre-and post-operation.Results The corneal exposure ratio was (87.34±4.15)％ on the left side and (87.22±3.77)％ on the right side in the beauties.In the 23 cases with suture method,the pre-and post-operation results were (83.02 ± 4.05)％ and (83.32 ±3.74)％ on the left side,(82.93 ±3.75)％ and (83.85±3.65)％ on the right side.In the 20 cases with incision method,the pre-and post-operation results were (64.05 ±4.53) ％ and(84.93±2.39)％ on the left side,(64.44 ±4.86)％ and (85.09 ±2.77)％ on the right side.Conclusions Corneal exposure ratio plays an important role in the eyelid aesthetic assessment.The measurement of Photoshop pixel method can provide an objective and precise assessment parameter for double eyelid blepharoplasty.

Objective To investigate the role of corneal exposure ratio in eyelid aesthetic assessment through the measurement by Photoshop pixel method in beauties and patients with double eyelid blepharoplasty.Methods 30 cases of female beauties and 43 cases with double eyelid blepharoplasty(23 cases with suture method and 20 cases with incision method) underwent measurement of corneal exposure ratio by Photoshop pixel method before operation and half a year after operation.The results were analyzed by SPSS 16.0 and compared between different sides or between pre-and post-operation.Results The corneal exposure ratio was (87.34±4.15)％ on the left side and (87.22±3.77)％ on the right side in the beauties.In the 23 cases with suture method,the pre-and post-operation results were (83.02 ± 4.05)％ and (83.32 ±3.74)％ on the left side,(82.93 ±3.75)％ and (83.85±3.65)％ on the right side.In the 20 cases with incision method,the pre-and post-operation results were (64.05 ±4.53) ％ and(84.93±2.39)％ on the left side,(64.44 ±4.86)％ and (85.09 ±2.77)％ on the right side.Conclusions Corneal exposure ratio plays an important role in the eyelid aesthetic assessment.The measurement of Photoshop pixel method can provide an objective and precise assessment parameter for double eyelid blepharoplasty.

Objective To investigate the safety and efficacy of ultrasound-guided thermal ablation in the treatment of rare liver tumors.Methods Clinical data of 9 patients with rare liver tumors who underwent ultrasound-guided thermal ablation from January 2012 to December 2016 in the Third Affiliated Hospital of Sun Yat-sen University were retrospectively analyzed.The informed consents of all patients were obtained and the local ethical committee approval was received.Among 9 cases (14 lesions),2 patients were male and 7 female,aged (42±12) years on average.All the patients underwent ultrasound or contrast-enhanced ultrasound-guided puncture and thermal ablation of the tumors.The ablation effect was evaluated immediately by contrast-enhanced ultrasound during the operation.The incidence of postoperative complications was observed.The complete ablation rate was evaluated by CT or MRI at postoperative 1 month.Results 11 lesions were treated with common ultrasound-guided thermal ablation and 3 lesions with contrast-enhanced ultrasound-guided ablation.The intraoperative complete ablation rate was 100％ (14/14),and the rate at postoperative 1 month was also 100％ (14/14).No ablation related complications was observed.During the follow-up,no local tumor progression or intrahepatic and extrahepatic tumors recurrence was observed in all patients.Conclusions For rare liver tumors,ultrasound-guided thermal ablation can achieve the effect of complete ablation,providing a new therapeutic option for the patients.

BACKGROUNDEndostar™ (rh-endostatin, YH-16) is a new recombinant human endostatin developed by Medgenn Bioengineering Co. Ltd., Yantai, Shandong, P.R.China. Pre-clinical study indicated that YH-16 could inhibit tumor endothelial cell proliferation, angiogenesis and tumor growth. Phase I and phase II studies revealed that YH-16 was effective as single agent with good tolerance in clinical use.The current study was to compare the response rate , median ti me to progression (TTP) ,clinical benefit andsafety in patients with advanced non-small cell lung cancer ( NSCLC) , who were treated with YH-16 plus vi-norelbine and cisplatin (NP) or placebo plus NP.

METHODSFour hundred and ninety-three histologically or cy-tologically confirmed stage IIIB and IV NSCLC patients , withlife expectancy > 3 months and ECOG perform-ance status 0-2 , were enrolledin a randomized ,double-blind ,placebo-controlled , multicenter trial ,either trialgroup : NP plus YH-16 (vinorelbine 25 mg/m² on day 1 and day 5 ,cisplatin 30mg/m² on days 2 to 4 , YH-167.5mg/m² on days 1 to 14) or control group : NP plus placebo (vinorelbine 25 mg/m² on day 1 and day 5 ,cis-platin 30 mg/m² on days 2 to 4 ,0.9% sodium-chloride 3 .75 ml on days 1 to 14) every 3 weeks for 2-6 cycles .The trial endpoints included response rate ,clinical benefit rate ,time to progression,quality of life and safety .

RESULTSOf 486 assessable patients , overall response rate was 35.4% in trial group and 19.5% in controlgroup (P=0 .0003) . The median TTP was 6 .3 months and 3 .6 months for trial group and control group respectively (P < 0 .001) . The clinical benefit rate was 73 .3 %in trial group and 64.0% in control group (P=0 .035) .In untreated patients of trial group and control group ,the response rate was 40 .0% and 23.9%(P=0 .003) ,the clinical benefit rate was 76 .5 % and 65 .0 % (P=0 .023) ,the median TTP was 6 .6 and 3 .7months (P=0 .0000) ,respectively .In pretreated patients of trial group and control group ,the response ratewas 23.9% and 8.5%(P=0 .034) ,the clinical benefit rate was 65.2% and 61.7%(P=0 .68) ,the median TTP was 5 .7 and 3 .2 months (P=0 .0002) ,respectively . The relief rate of clinical symptoms in trial groupwas higher than that of those in control group ,but no significance existed (P > 0 .05) . The score of quality oflife in trial group was significantly higher than that in control group (P=0 .0155) after treatment . There were no significant differences in incidence of hematologic and non-hematologic toxicity , moderate and severe sideeffects betweentrial group and control group .

CONCLUSIONSThe addition of YH-16 to NP regimen results in significantly and clinically meaningful improvement in response rate , median time to tumor progression,and clinical benefit rate compared with NP alone in advanced NSCLC patients . YH-16 in combination with chemotherapy shows a synergic activity and a favorable toxic profile in advanced cancer patients .